According to the same poll, 40% of users say they took them primarily for weight loss, while 60% were using GLP-1s to treat a chronic condition including diabetes or heart disease
When taken at the recommended dosage, GLP-1s can cause unwanted side effects, like nausea, GI issues, and dizziness
The addition of fibrin encapsulation further enhanced differentiation efficiency and structural integrity
In March 2024, the FDA expanded Wegovys approval to include reducing cardiovascular risk in people with obesity and existing cardiovascular diseasea major milestone for these treatments
2 Majority of patients were treated with standard of care 1,2,n,o Summary of medication at baseline (N=3533) 1,2 Select CV and CKD baseline characteristics (N=3533) 1,2 n At baseline patients in FLOW were receiving standard-of-care background therapy, including a maximum tolerated label dose of a RAAS-blocking agent including an ACE inhibitor or an ARB, unless such treatment was contraindicated or not tolerated
Many people face genetic, metabolic, or hormonal challenges that make weight loss harder than it should be
